arrow
J

Joost S.P. Vermaat

leiden university medical center
H指数:24
被引数:3,227

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nivolumab consolidation in patients with double and triple hit high-grade B-cell lymphoma in complete metabolic remission after DA-EPOCH-R

Nivolumab巩固治疗在完成DA-EPOCH-R方案后达到完全代谢缓解的双打击和三打击高危B细胞淋巴瘤患者中的应用

2026-10-300
OA
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma

使用epcoritamab联合 bendamustine和rituximab的一线治疗在滤泡性淋巴瘤患者中诱导了超过3年的持续缓解

2026-08-050
OAAI
Risk of thrombosis and bleeding following CAR T-cell therapy: Insights from the Dutch “Follow that CAR!” registry

CAR T细胞疗法后的血栓和出血风险:来自荷兰“Follow that CAR!”登记研究的见解

2026-07-280
OAAI
Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma

固定疗程的Epcoritamab联合R2方案可改善复发或难治性滤泡性淋巴瘤患者的预后。

Blood
IF23.1
2025-09-100
OAAI
Phase 1b and Dose-Expansion Study of GSK3326595, a PRMT5 Inhibitor as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cancers

GSK3326595的1b期和剂量扩展研究,PRMT5抑制剂作为单一疗法并与Pembrolizumab联合用于晚期癌症患者

2025-09-090
PREAI
Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment

骨内弥漫性大B细胞淋巴瘤中,免疫富集肿瘤微环境与更优生存率相关。

2025-04-290
OA
Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP

Atezolizumab巩固治疗在完成R-CHOP治疗后达到完全缓解的高危弥漫性大B细胞淋巴瘤患者中的应用

2025-04-210
OA
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies
2024-12-010
PRE
Immunosuppressed Tumor Microenvironment in MYC-Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

MYC重排的高级别B细胞淋巴瘤与未特别指明的弥漫性大B细胞淋巴瘤相比的免疫抑制性肿瘤微环境

BLOOD
IF23.1
2024-11-050
PRE
Population-Based External Validation of the CAR-Hematotox Score to Predict CAR T Cell Related Toxicity and Outcome in R/R LBCL Patients

基于人群的外部验证:CAR-Hematotox评分在预测R/R LBCL患者CAR T细胞相关毒性和结局中的应用

BLOOD
IF23.1
2024-11-050
PRE
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
LEUKEMIA
IF13.4
2024-07-230
OAAI
Treatment-specific risk of subsequent malignant neoplasms in five-year survivors of diffuse large B-cell lymphoma
2024-02-014
OAAI